The Global Research on the Impact of Dermatological Diseases (GRIDD) project is the first global patient impact project in the history of dermatology. It aims to collect global data on the impact of dermatological diseases directly from patients.
The GRIDD data will support local, national, and international advocacy work for more research, better treatments, and healthcare policies, and, ultimately, will improve the lives of dermatology patients. For the first time, dermatology patients around the world and from all disease types will contribute to a dataset that measures the true impact of living with their diseases.
Tools & Resources
The Global Research on the Impact of Dermatological Diseases (GRIDD) project team has developed tools that you, as the disease expert can share with your community.
The GRIDD Study will be live from June 5 through December 31. The primary goal of the study is to capture responses from 10,000 dermatology patients from as many regions and dermatological conditions as possible.
Below you will find tools for both Patient Organizations that are GlobalSkin Members, and all other Stakeholders. Each toolkit can be downloaded as a PDF, as well as a downloadable zipped file where you will find social cards, logos, as well as the Word document version of the toolkit for ease of use.
We thank you in advance for your participation in the GRIDD Study and for working with us to share this unprecedented opportunity with your patient communities.
GRIDD Study Explainer Cartoon
A new short GRIDD video that explains the purpose of the Study. This benefit-driven video can be easily viewed and shared on absolutely all social media platforms.
View on YouTube and Share this link The GRIDD Study - YouTube
GRIDD Study Messaging
Easy-to-use GRIDD Study messaging showing the value of participation to your patient communities, focusing on the challenges patients experience (Mental Health, Affordability, Accessibility, Policy, Measure, and General).
New GRIDD Social Media Cards (Blanks)
Download these new blank social media cards which can be co-branded and customized with messaging from the Value Proposition document with statements that particularly resonate with your Members.
New GRIDD Social Media Cards
Download these new social media cards focused on the different challenges patients experience (Mental Health, Affordability, Accessibility, Policy, Measure, and General).
GlobalSkin Member Toolkit
You, our Members, will be key partners in helping us to reach this important goal of 10,000 GRIDD participants. We thank you in advance for your participation in the GRIDD Study and for working with
us to share this unprecedented opportunity with your patient communities. We are providing you with easily shareable information & resources.
To inspire your network and motivate them to generate interest among patients for active participation in this groundbreaking research, we are providing you with easily shareable information and resources. These materials effectively convey the significance and benefits of involvement in this trailblazing study and help foster enthusiasm among stakeholders as they tell others about the initiative.
Double Sided Postcard
This double-sided 4"X6" postcard can be used as a perfect tool for any special event or printed for any establishment where dermatology patients gather.
Participate in this ground-breaking GRIDD study now!
The GRIDD data will support local, national, and international advocacy work for more research, better treatments and healthcare policies, and, ultimately, will improve the lives of dermatology patients.
Who Can Participate?
- People who are over 18 years old
- People who have a dermatological condition
- People who can understand and read one of these 17 languages to a level sufficient to complete the survey independently (English, Arabic, Bengali, Simplified Chinese, Danish, Dutch, French, German, Hindi, Italian, Japanese, Portuguese, Russian, Serbian, Spanish, Swahili, or Vietnamese.)
The online survey takes 10-20 minutes to complete and is open only until December 31, 2023.